Results 81 to 90 of about 27,592 (211)

Pharmacokinetic non-interaction analysis in a fixed-dose formulation in combination of atorvastatin and ezetimibe

Frontiers in Pharmacology, 2014
Recent clinical research has shown that atorvastatin in combination with cholesterol absorption inhibitor ezetimibe significantly reduces LDL-C level in patients with hypercholesterolemia, showing a superior lipid-lowering efficacy compared to statin ...
Omar ePatiño-Rodríguez, Irma eTorres-Roque, Maricela eMartínez-Delgado, Abraham eEscobedo-Moratilla, José ePérez-Urizar   +4 more
doaj   +1 more source

Entrapment of a Ventricular Lead and Guiding Catheter During Left Bundle Branch Area Pacing: A Stepwise Retrieval Approach

Journal of Arrhythmia, Volume 42, Issue 2, April 2026.
Entrapment of a ventricular lead and guiding catheter during left bundle branch area pacing is a rare but serious complication. A stepwise bailout strategy using bidirectional traction via femoral access and biopsy forceps enabled safe and successful retrieval without surgical intervention.
Daiki Yamashita, Yoshihiko Kagawa, Ayaka Ino, Tairo Kurita, Kaoru Dohi   +4 more
wiley   +1 more source

Ezetimibe inhibits the migration and invasion of triple‐negative breast cancer cells by targeting TGFβ2 and EMT

FEBS Open Bio
The important role of cholesterol in tumor metastasis has been widely studied in recent years. Ezetimibe is currently the only selective cholesterol uptake inhibitor on the market.
Lingkai Kong, Qinyu He, Ding Ma, Weiwei Shi, Qilei Xin, Chunping Jiang, Junhua Wu   +6 more
doaj   +1 more source

Clinical efficacy and safety of Ezetimibe on major cardiovascular endpoints: systematic review and meta-analysis of randomized controlled trials.

PLoS ONE, 2015
BackgroundRandomized clinical trials (RCTs) about Ezetimibe's efficacy on patient-oriented outcomes have given discordant results. The aim of this study was to determine the net effect of Ezetimibe and of the widely marketed combination, Ezetimibe ...
Alessandro Battaggia, Alberto Donzelli, Maria Font, Davide Molteni, Antonio Galvano   +4 more
doaj   +1 more source

Curcumin inhibits cholesterol uptake in Caco-2 cells by down-regulation of NPC1L1 expression [PDF]

, 2010
Background: Curcumin is a polyphenol and the one of the principle curcuminoids of the spice turmeric. Its antioxidant, anti-cancer and anti-inflammatory effects have been intensively studied.
Dan Feng, Lena Ohlsson, Rui-Dong Duan
core   +2 more sources

The use of different types of networks, alone and in combination, for drug target identification

British Journal of Pharmacology, Volume 183, Issue 8, Page 1653-1662, April 2026.
Current therapeutic approaches often focus on targeting clinical symptoms or peripheral phenotypes rather than the underlying molecular mechanisms, or endophenotypes, that drive diseases. While symptom‐based drugs can alleviate discomfort, they do not necessarily alter disease progression and may overlook opportunities for prevention or early ...
Paolo Parini
wiley   +1 more source

Pharmacokinetic and pharmacodynamic interaction between ezetimibe and rosuvastatin in healthy male subjects

Drug Design, Development and Therapy, 2017
Chang Hee Kim,1 Hyungmi An,2 Sung Hye Kim,3 Dongseong Shin4 1Department of Urology, Gachon University Gil Medical Center, Incheon, 2Department of Statistics, Seoul National University, Seoul, 3Clinical Development, Navipharm Co., Ltd., Suwon ...
Kim CH, An H, Kim SH, Shin D
doaj  

A Validated Reversed-Phase HPLC Method for the Determination of Atorvastatin Calcium in Tablets [PDF]

, 2014
A Reversed-Phase Liquid Chromatographic (RP-LC) assay method was developed for the quantitative determination of atorvastatin calcium in the presence of its degradation products.
Ferello, L., Repetto, M. F., Segall, Adriana Ines, Simionato, Laura Daniela, Stamer. S., Zubata, P. D.   +5 more
core  

Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial [PDF]

, 2009
<br>Background: Metformin reduces cardiovascular risk in patients with type 2 diabetes seemingly independent of lowering blood glucose concentration. We assessed the cardiovascular effects of metformin in individuals without type 2 diabetes.</br&
Eddy, Despres, Grundy, Bird, Seifarth, Nathan, Fontbonne, Charles, Holman, Kooy, Knowler, Alberti, Vergeer, Touboul, Liang, Spence, Levey, Meaney, Taylor, Selvin, Boussageon, Sjöström, Shyangdan, de Jager, Bots, Taylor, Boden, Huang, Baigent, Lorenz, Mazzone, Taylor, Lonn, Lexis   +33 more
core   +5 more sources

Targeting inflammation in cardiometabolic disease: Icosapent ethyl modulates monocyte‐derived macrophages isolated from patients with cardiovascular disease with or without type 2 diabetes

Diabetic Medicine, Volume 43, Issue 4, April 2026.
Abstract Aims Despite intensive lipid‐lowering therapy, individuals with atherosclerotic cardiovascular disease (ASCVD) exhibit residual inflammatory risk, which drives recurrent cardiovascular events. This risk is amplified in type 2 diabetes mellitus (T2DM), where a pro‐inflammatory milieu accelerates atherogenesis. Monocyte‐derived macrophages (MDMs)
J. K. Ward, M. U. Shah, K. Lee, P. E. Squires, C. E. Hills   +4 more
wiley   +1 more source